Price (GBX)
8,000.00 -% (-)
AZNORD SHS $0.25
Track 6 more instruments
Open / Last close
8,186.00 / 8,000.00
High / Low
8,188.00 / 8,000.00
Bid / Offer
8,002.00 / 8,005.00
Turnover
£190,281,035.19
Special Condition: -
Trading Status: Market Close
As at 24.11.20 23:45:51 - All data delayed at least 15 minutes
6 more instruments

AstraZeneca Plc instruments

Select instrument to view
Equity (2)
Code Instrument name Price Change Type Documentation
AZNORD SHS $0.258,000.00
GBX
-Equity-
0A4JASTRAZENECA ADR REPRESENTING 1.5 ORD SHS-
USD
-Equity-
Bonds (5)
Code Instrument name Price Maturity Type Documentation
35BR0.750% NTS 12/05/24-
EUR
12.05.24Bonds-
35BZ1.250% NTS 12/05/28-
EUR
12.05.28Bonds-
35CA0.250% NTS 12/05/21-
EUR
12.05.21Bonds-
43ER0.875% NTS 24/11/21-
EUR
24.11.21Bonds-
50UC5.75% NTS 13/11/31144.00
GBP
13.11.31Bonds-

Price information

What's this?
Open price
8,186.00
Previous close price / date
8,000.00 / 24 November 2020
Volume
2,846,621
Turnover (on book)
£190,281,035.19
52 week range
6,221.00 / 9,320.00
YTD return
4.44
1 year return
6.16

Instrument information

What's this?
Market
Main Market
Instrument market cap (£m)
104,984.60
Earnings per share
1.03
Issue date
13 January 2006
ISIN
GB0009895292
SEDOL
0989529
Market identifier code (MIC)
XLON
Country of share register
GB
Market segment
SET1
Trading service
SETS
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
24.11.20 18:27:52 8,001.00 GBX 750 60,007.50 Off-Book TNCP XOFF
24.11.20 18:25:10 8,041.68 GBX 628 50,501.75 Off-Book TNCP XOFF
24.11.20 18:24:11 8,059.00 GBX 3,126 251,924.34 Off-Book TNCP XOFF
24.11.20 17:48:29 8,001.10 GBX 69 5,520.76 Off-Book TNCP XOFF
24.11.20 18:09:50 8,034.03 GBX 28,000 2,249,527.28 Off-Book TNCP XOFF

Upcoming Events

from AstraZeneca Plc
AstraZeneca results and presentations
March 31st 2020, 11:00:00pm

Duration: + Add to my Calendar

Equity Research

from AstraZeneca Plc
Material Q3 growth moderation, but profitability improvement continued

Compared with H1 20, AstraZeneca witnessed a pertinent slowdown in Q3 sales growth. Growth was again driven by Oncology and aptly supported by the New CVRM, while R&I was weak. However, the recovery in profitability was sustained – especially on the back of sales & marketing activities of the earlie ...

View report
SP Angel Healthcare Conditions- 12-10-2020

View report
EVENT: Yellowstone Advisory Webinar with Simon Young

Unearthing winners, avoiding losers and learning from mistakes

View report
An assessment of Astra’s COVID-19 vaccine journey

AstraZeneca (an inexperienced vaccine player) has emerged as top contender in the COVID-19 vaccine race, post its deal with Oxford University. The potential vaccine’s much-lower price and multiple out-licensing deals, resulting in major capacities being secured, have been two critical miles ...

View report
Growth continued in Q2, profitability better but more to be achieved

AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a front-runner in the COVID-19 vaccine race. While there were some profitability improvements as wel ...

View report

Contacts

from AstraZeneca Plc
Thomas Kudsk Larsen
atAstraZeneca Plc
+44 203 749 5712
thomas.larsen@astrazeneca.com
Oncology
Henry Wheeler
atAstraZeneca Plc
+44 203 749 5797
henry.wheeler@astrazeneca.com
BioPharmaceuticals (CV, metabolism)
Christer Gruvris
atAstraZeneca Plc
+44 203 749 5711
christer.gruvris@astrazeneca.com
BioPharmaceuticals (respiratory, renal)
Nick Stone
atAstraZeneca Plc
+44 203 749 5716
nick.stone@astrazeneca.com
Other medicines
Josie Afolabi
atAstraZeneca Plc
+44 203 749 5631
josie.afolabi@astrazeneca.com
Finance, fixed income
Craig Marks
atAstraZeneca Plc
+44 7881 615 764
craig.marks@astrazeneca.com
Corporate access, retail investors
Jennifer Kretzmann
atAstraZeneca Plc
+44 203 749 5824
jennifer.kretzmann@astrazeneca.com
Issuer presentations live and on demand
Watch on Spark Live